AA
AVEO

ALPS Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

ALPS Advisors’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-35,325
Closed -$197K – 1108
2022
Q1 		$197K Sell
35,325
-4,450
-11% -$18.3K ﹤0.01% 805
2021
Q4 		$187K Sell
39,775
-2,349
-6% -$14.6K ﹤0.01% 878
2021
Q3 		$260K Sell
42,124
-3,130
-7% -$18.7K ﹤0.01% 881
2021
Q2 		$298K Buy
+45,254
New +$312K ﹤0.01% 837

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

ALPS Advisors's AVEO Position: Q2 2022 in Review

ALPS Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2022, closing a stake of 35,325 shares — an estimated $197K sold.

ALPS Advisors first reported a position in AVEO in Q2 2021 and held it in 4 quarters. The position peaked at $298K in Q2 2021. 56 funds tracked by Wall St. Rank hold AVEO as of Q2 2022.

  • ALPS Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • ALPS Advisors sold 35,325 AVEO Pharmaceuticals, Inc. shares in Q2 2022, an estimated $197K.
  • ALPS Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2021 and held it in 4 quarters.
  • ALPS Advisors's AVEO Pharmaceuticals, Inc. position peaked at $298K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.